Prostate Cancer Clinical Trial
Official title:
PCA-3 Gene Project
Nowadays, prostate cancer screening is largely widespread although it is not recommended
yet. This screening includes primarily digital rectal examination and PSA.
Recently, a new specific genetic marker of prostate cancer has been discovered. It is PCA-3
gene.
The main objective is to evaluate prospectively this new marker in patients treated for
prostatic pathology (benign or malign) in the department.
Nowadays, prostate cancer screening is largely widespread although it is not recommended
yet. This screening includes primarily digital rectal examination and PSA.
The main drawback is the poor PSA specificity. Prostate cancer diagnosis is only histologic
diagnosis (mainly by prostate biopsies). However, prostate needle biopsies have a poor
rentability and are negative in 60 to 80%. Recently, a new specific genetic marker of
prostate cancer has been discovered. It is PCA-3 gene. This gene encodes for RNAm noncoding.
So, RNA expression must be assayed by RT-PCR. The main objective is to evaluate
prospectively this new marker in patients treated for prostatic pathology (benign or malign)
in the department.
PCA-3 assay will be made from urine specimens collected by vesical catheterism just before
surgery. Moreover, the investigators will analyse expression of several prostatic markers
(genes coding for androgen receptor and steroid alpha-reductase type 1 and 2). The main
objective is to improve the prostate cancer diagnosis specificity. Gene expression will be
assayed by RT-PCR.
Prostatic cells in urine specimens will be confirmed by assay of PSA gene expression.
Normalization of data will be performed using 3 housekeeping genes expression (ß-actin,
K-a-1 tubulin and Glyceraldehyde-3-phosphate).
The originality of this clinical study compared to previous reports, consists to two
elements. Firstly, all patients included in our study will be operated for a prostate cancer
or a BPH. So, the risk to ignore a prostate cancer will be low unlike prostate biopsies made
for a prostate cancer screening. Secondly, PCA-3 assay will be coupled with others prostatic
specific markers.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |